PERSONAL INFORMATION	Emanuele Guardalben 	

	 +    	
	 emanuele.guardalben@gmail.com 	
	Sex Male | Date of birth 03/09/1985 | Nationality Italian 	

EDUCATION AND TRAINING	 	

Sep 1999–Jul 2004	High-school diploma	EQF level 4	
	Liceo Scientifico A. Messedaglia, Verona (Italy) 	

Oct 2004–Jul 2010	Bachelor's degree in Medicine and Surgery	EQF level 6	
	Università degli Studi di Verona, Verona (Italy) 	

30 Jun 2011–29 Jun 2016	Postgraduate Specialization in Haematology	EQF level 7	
	Università degli Studi di Verona, Verona (Italy) 	

WORK EXPERIENCE	 	

1 Aug 2016–Present	Research fellow	
	Università degli Studi di Ferrara, Ferrara (Italy) 	

PERSONAL SKILLS	 	

Mother tongue(s)	Italian	
		
Other language(s)	UNDERSTANDING	SPEAKING	WRITING	
	Listening	Reading	Spoken interaction	Spoken production		
English	B1	C2	B1	B1	B2	
	Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages 	

Job-related skills	- participation as sub-investigator in following clinical trials: 
MO25455 (A randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin's lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously) 
BO21005 (GOYA - A Phase III, multicenter, open-label, randomized trial comparing the efficacy of GA101 (RO5072759) in combination with CHOP (G-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL)), 
CC-5013-DLC-002 (ROBUST - Phase 3 randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and safety of lenalidomide (CC-5013) plus R-CHOP chemotherapy (R2-CHOP) versus placebo plus R_CHOP chemotherapy in subjects with previously untreated activated B-cell type diffuse large b-cell lymphoma)
LLC1114 (A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL).
ACE-CL-006 (A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia)

- participation as sub-investigator in the Named Patient Program of Ibrutinib in patients with Chronic Lymphatic Leukemia and Mantle Cell Lymphoma.	

ADDITIONAL INFORMATION	 	

Publications	Pro-apoptotic activity of a-bisabolol in preclinical models of primary human acute leukemia cells. Cavalieri E, Rigo A, Bonifacio M, Carcereri de Prati A, Guardalben E, Bergamini C, Fato R, Pizzolo G, Suzuki H, Vinante F. J Transl Med. 2011;9:45.
a-bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib. Bonifacio M, Rigo A, Guardalben E, Bergamini C, Cavalieri E, Fato R, Pizzolo G, Suzuki H, Vinante F. PLoS One. 2012;7(10):e46674.
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. Tiribelli M, Bonifacio M, Calistri E, Binotto G, Maino E, Marin L, Guardalben E, Branca A, Gherlinzoni F, Semenzato G, Sancetta R, Pizzolo G, Fanin R. Leuk Res. 2013;37(11):1457-60. 
PBX/E2A transcript positive B lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. Carli G, Ferrarini I, Guardalben E, Bonifacio M, Meneghini V, Visco C, Ambrosetti A. Ann Hematol Oncol. 2015;2(1):1017.
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. Rigolin GM, Formigaro L, Cavallari M, Quaglia FM, Lista E, Urso A, Guardalben E, Martinelli S, Saccenti E, Bassi C, Lupini L, Bardi MA, Volta E, Tammiso E, Melandri A, Negrini M, Cavazzini F, Cuneo A. Oncotarget. 2017;8(17):28008-28020.
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Rigolin GM, Cavallari M, Quaglia FM, Formigaro L, Lista E, Urso A, Guardalben E, Liberatore C, Faraci D, Saccenti E, Bassi C, Lupini L, Bardi MA, Volta E, Tammiso E, Melandri A, Negrini M, Cavazzini F, Cuneo A.  Blood. 2017. prepublished online April 26, 2017; DOI 10.1182/blood-2017-03-772285
Mitochondrial-Mediated Apoptosis by the Sesquiterpene Oil α-Bisabolol and Its Synergism with Imatinib and Nilotinib in BCR-ABL+ Cells. Bonifacio M, Rigo A, Cavalieri E,​ Guardalben E, Bergamini C, Pizzolo G, Suzuki H, Vinante F. Blood, 2010 ASH annual meeting abstracts; 116 (21).
Sesquiterpene oil a-bisabolol, which binds to BID in lipid rafts, induces apoptosis in bcr/abl+ cell lines through membrane depolarization. Guardalben E, Bonifacio M, Rigo A, Cavalieri E, Bergamini C, Pizzolo G, Suzuki H, Vinante F. Haematologica (Abstract) 2011.
PBX/E2A transcript positive B lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. Carli G, Guardalben E, Bonifacio M, Meneghini V, Tecchio C, Cucca M, Pizzolo G, Ambrosetti A. Haematologica (Abstract) 2013. 
Ofatumumab and Lenalidomide preferentially inhibit B-cell receptor signaling in Chronic Lymphocytic Leukemia cells with mutated IGHV. Cavallini C, Guardalben E, Ambrosetti A, Veneri D, Pizzolo G, Scupoli MT. EHA abstract book, 2016: E1029.